Literature DB >> 17003614

Association between osteonecrosis of the jaws and chronic high-dosage intravenous bisphosphonates therapy.

Filippo Graziani1, Silvia Cei, Fabio La Ferla, Elisa Cerri, Angelo Itro, Mario Gabriele.   

Abstract

Bisphosphonates (BPs) are used to inhibit bone resorption. Recently, they have been used in cancer patients to prevent bone loss due to bone metastasis. Fourteen consecutive patients, undergoing BPs monthly IV infusion due to neoplastic bone diseases, were diagnosed with osteonecrosis of the jaws. None of the patients had been previously undergoing radiotherapy of the head and neck region. Eight patients showed maxillary involvement, and nine patients had had a recent tooth extraction in the osteonecrosis areas. Biopsies and surgical debridment were performed. Histologically, none of the patients showed signs of bone metastasis. As high-dosage long-term BP therapy appears to be associated with osteonecrosis of the jaws, dental practitioners should exercise caution in the treatment of such patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003614     DOI: 10.1097/01.scs.0000221517.80361.6f

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  3 in total

1.  Conservative surgical treatment in the management of BRONJ: a case series of 129 consecutive cases.

Authors:  M Gabriele; F La Ferla; S Cei; M Nisi; F Graziani
Journal:  Ann Stomatol (Roma)       Date:  2013-10-24

2.  Platelet-Rich Plasma in Treatment of Zoledronic Acid-Induced Bisphosphonate-related Osteonecrosis of the Jaws.

Authors:  Farzin Sarkarat; Mohammad Hosein Kalantar Motamedi; Jahanfar Jahanbani; Dena Sepehri; Roozbeh Kahali; Zahra Nematollahi
Journal:  Trauma Mon       Date:  2014-03-18

3.  An Approach for the Prevention, Diagnosis, and Treatment of Jaw Osteonecrosis: Report of a Case Associated with Zoledronic Acid.

Authors:  Danila S de Alexandria Santos; Marco Vinícius de Sales Lima; Alexandre do Prado Scherma; Dárcio Kitakawa; Natália de Castro Magalhães; Felipe da Silva Peralta; Luis Felipe das Chagas E Silva de Carvalho
Journal:  Am J Case Rep       Date:  2020-11-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.